Javier San Martin
Technik-/Wissenschafts-/F&E-Leiter bei ATHIRA PHARMA, INC.
Vermögen: 4 Mio $ am 30.04.2024
Aktive Positionen von Javier San Martin
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ATHIRA PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 15.04.2024 | - |
Karriereverlauf von Javier San Martin
Ehemalige bekannte Positionen von Javier San Martin
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 18.11.2019 | 01.02.2024 |
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01.12.2013 | 01.11.2019 |
| AMGEN INC. | Corporate Officer/Principal | - | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - | - |
| ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Ausbildung von Javier San Martin
| University of Buenos Aires School of Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
| Argentinien | 2 |
Operativ
| Corporate Officer/Principal | 4 |
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 7 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| AMGEN INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| ATHIRA PHARMA, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
- Börse
- Insiders
- Javier San Martin
- Erfahrung
